Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
12th January 2021 | Andre Turenne | 10,443 | Open or private sale | $8.62 | $90,018.66 |
12th January 2021 | Allison Dorval | 2,942 | Open or private sale | $8.62 | $25,360.04 |
21st May 2020 | Omar Khwaja | 3,500 | Open or private sale | $12.96 | $45,360.00 |
3rd April 2020 | Robert W. Hesslein | 3,091 | Open or private sale | $8.51 | $26,304.41 |
10th February 2020 | Robert W. Hesslein | 27,500 | Grant/award etc. | $0.00 | |
10th February 2020 | Omar Khwaja | 30,000 | Grant/award etc. | $0.00 | |
10th February 2020 | Andre Turenne | 81,250 | Grant/award etc. | $0.00 | |
10th February 2020 | Allison Dorval | 27,500 | Grant/award etc. | $0.00 | |
21st January 2020 | Allison Dorval | 3,128 | Open or private sale | $13.36 | $41,790.08 |
21st January 2020 | Andre Turenne | 10,705 | Open or private sale | $13.36 | $143,018.80 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
18th January 2021
17th November 2020
6th November 2020